Ticker
ADVM

Price
1.19
Stock movement down
-0.06 (-4.80%)
Company name
Adverum Biotechnologies Inc
Exchange
(NASDAQ
,
Currency
USD
)
Sector
Healthcare >
Biotechnology
Market cap
117.54M
Ent value
152.33M
Price/Sales
-
Price/Book
0.42
Div yield
-
Div growth
-
Growth years
-
FCF payout
-
Trailing P/E
-
Forward P/E
-
PEG
-
EPS growth
-
1 year return
-50.42%
3 year return
-51.94%
5 year return
-13.62%
10 year return
-
Last updated: 2022-08-25

DIVIDENDS

ADVM does not pay dividends

VALUATION

Valuation Ratios

Loading...
Valuation Ratios data
Trailing P/E-
Price to OCF-
Price to FCF-
Price to EBITDA-
EV to EBITDA-

Valuation (Sales/Book Value)

Loading...
Valuation (Sales/Book Value) data
Price to Sales-
Price to Book0.42
EV to Sales-

FINANCIALS

Per share

Loading...
Per share data
Current share count98.77M
EPS (TTM)-1.58
FCF per share (TTM)-1.35

Income statement

Loading...
Income statement data
Revenue (TTM)0.00
Gross profit (TTM)0.00
Operating income (TTM)-155.61M
Net income (TTM)-155.01M
EPS (TTM)-1.58
EPS (1y forward)-1.26

Margins

Loading...
Margins data
Gross margin (TTM)-
Operating margin (TTM)-
Profit margin (TTM)-

Balance Sheet

Loading...
Please create a free account or log in to access this chart
Balance Sheet data
Cash89.65M
Net receivables220.00K
Total current assets280.12M
Goodwill0.00
Intangible assets0.00
Property, plant and equipment37.22M
Total assets407.39M
Accounts payable3.25M
Short/Current long term debt102.54M
Total current liabilities23.24M
Total liabilities124.44M
Shareholder's equity282.95M
Net tangible assets282.95M

Cash flow

Loading...
Please create a free account or log in to access this chart
Cash flow data
Operating cash flow (TTM)-114.45M
Capital expenditures (TTM)18.09M
Free cash flow (TTM)-132.55M
Dividends paid (TTM)0.00

Financial returns

Loading...
Please create a free account or log in to access this chart
Financial returns data
Return on Equity-54.78%
Return on Assets-38.05%
Return on Invested Capital-54.33%
Cash Return on Invested Capital-46.46%

STOCK INFORMATION

Stock chart

Loading...
Stock price data
Open1.25
Daily high1.30
Daily low1.17
Daily Volume402K
All-time high60.08
1y analyst estimate4.33
Beta1.00
EPS (TTM)-1.58
Dividend per share-
Ex-div date-
Next earnings date2 Nov 2022

Downside potential

Loading...
Downside potential data
ADVMS&P500
Current price drop from All-time high-98.02%-12.18%
Highest price drop-98.65%-56.47%
Date of highest drop16 May 20229 Mar 2009
Avg drop from high-81.56%-11.38%
Avg time to new high73 days12 days
Max time to new high1923 days1805 days
COMPANY DETAILS
ADVM (Adverum Biotechnologies Inc) company logo
Marketcap
117.54M
Marketcap category
Small-cap
Description
Adverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; Cornell University; GenSight; Lexeo; and Virovek. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
Employees
188
Investor relations
-
SEC filings
CEO
Leone D. Patterson
Country
USA
City
Redwood City
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
September 23, 2022
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
September 23, 2022
REDWOOD CITY, Calif., Sept. 23, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
September 23, 2022
Adverum (ADVM) initiates dosing in the phase II LUNA study, currently investigating its lead product candidate ixoberogene soroparvovec for wet age-related macular degeneration.
September 15, 2022
LUNA Phase 2 Study in Wet AMD - Study Design Objective: The LUNA trial is a multicenter, double-masked, randomized, parallel-group Phase 2 study evaluating a one-time IVT injection of either of two do...
September 14, 2022
REDWOOD CITY, Calif., Sept. 08, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly...
September 8, 2022
REDWOOD CITY, Calif., Aug. 26, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
August 26, 2022
- Dosing first Phase 2 LUNA trial participant with ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) on track for the third quarter of 2022 and preliminary data anticipated througho...
August 11, 2022
REDWOOD CITY, Calif., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
August 10, 2022
REDWOOD CITY, Calif., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company that aims to establish gene therapy as a new standard of care for highly ...
August 1, 2022
Next page